These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Healthcare resource utilization and costs before and after lacosamide initiation as adjunctive therapy among patients with epilepsy in the United States. Fishman J; Martin M; Labiner DM; Lew CR; Johnson BH Epilepsy Behav; 2019 Oct; 99():106331. PubMed ID: 31399339 [TBL] [Abstract][Full Text] [Related]
3. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Manjunath R; Paradis PE; Parisé H; Lafeuille MH; Bowers B; Duh MS; Lefebvre P; Faught E Neurology; 2012 Oct; 79(18):1908-16. PubMed ID: 23077014 [TBL] [Abstract][Full Text] [Related]
4. Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use. Cramer JA; Wang ZJ; Chang E; Copher R; Cherepanov D; Broder MS Epilepsy Behav; 2015 Mar; 44():40-6. PubMed ID: 25635369 [TBL] [Abstract][Full Text] [Related]
5. Economic impact of epilepsy and the cost of nonadherence to antiepileptic drugs in older Medicare beneficiaries. Ip Q; Malone DC; Chong J; Harris RB; Labiner DM Epilepsy Behav; 2018 Mar; 80():208-214. PubMed ID: 29414554 [TBL] [Abstract][Full Text] [Related]
6. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224 [TBL] [Abstract][Full Text] [Related]
7. Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims. Shcherbakova N; Rascati K; Brown C; Lawson K; Novak S; Richards KM; Yoder L CNS Drugs; 2014 Nov; 28(11):1047-58. PubMed ID: 25086640 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Davis KL; Candrilli SD; Edin HM Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549 [TBL] [Abstract][Full Text] [Related]
9. Seizure clusters, treatment patterns, and healthcare resource utilization in patients with epilepsy: A Wisconsin-based claims analysis. Morris GL; Eads P; Tryfon M; Ems D Epilepsy Behav; 2024 Aug; 157():109867. PubMed ID: 38824751 [TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization and costs in adults with stable and uncontrolled epilepsy. Cramer JA; Wang ZJ; Chang E; Powers A; Copher R; Cherepanov D; Broder MS Epilepsy Behav; 2014 Feb; 31():356-62. PubMed ID: 24239435 [TBL] [Abstract][Full Text] [Related]
11. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study. Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Ettinger AB; Manjunath R; Candrilli SD; Davis KL Epilepsy Behav; 2009 Feb; 14(2):324-9. PubMed ID: 19028602 [TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases. Fuldeore M; Yang H; Du EX; Soliman AM; Wu EQ; Winkel C Fertil Steril; 2015 Jan; 103(1):163-71. PubMed ID: 25455535 [TBL] [Abstract][Full Text] [Related]
14. The direct cost of seizure events in severe childhood-onset epilepsies: A retrospective claims-based analysis. Reaven NL; Funk SE; Lyons PD; Story TJ Epilepsy Behav; 2019 Apr; 93():65-72. PubMed ID: 30831405 [TBL] [Abstract][Full Text] [Related]
15. Healthcare utilization and costs in children with stable and uncontrolled epilepsy. Cramer JA; Wang ZJ; Chang E; Powers A; Copher R; Cherepanov D; Broder MS Epilepsy Behav; 2014 Mar; 32():135-41. PubMed ID: 24561658 [TBL] [Abstract][Full Text] [Related]
16. Health care cost associated with the use of enzyme-inducing and non-enzyme-active antiepileptic drugs in the UK: a long-term retrospective matched cohort study. Borghs S; Thieffry S; Noack-Rink M; Dedeken P; Hong LS; Byram L; Logan J; Chan J; Kiri V BMC Neurol; 2017 Mar; 17(1):59. PubMed ID: 28335764 [TBL] [Abstract][Full Text] [Related]
17. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643 [TBL] [Abstract][Full Text] [Related]
18. Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: A US database analysis. Faught E; Helmers S; Thurman D; Kim H; Kalilani L Epilepsy Behav; 2018 Aug; 85():37-44. PubMed ID: 29906700 [TBL] [Abstract][Full Text] [Related]
19. Bioequivalent antiepileptic drug switching and the risk of seizure-related events. Hansen RN; Nguyen HP; Sullivan SD Epilepsy Res; 2013 Sep; 106(1-2):237-43. PubMed ID: 23726541 [TBL] [Abstract][Full Text] [Related]
20. Economic burden associated with the use of generic antiepileptic drugs in the United States. Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]